As several pro-survival RTKs (e.g., epidermal growth factor receptor (EGFR), hepatocyte growth factor receptor (MET), Insulin-like growth factor 1 receptor (IGF1R)) depend on these functions, inhibiting ROR1 in lung cancer was proposed as a novel shortcut to bypass resistance to EGFR tyrosine kinase inhibitors [96]. Here, IGF1R is linked to lung cancer.